Hi-TIDe : T cell engineering

| Research interest | Research group projects | Selected Publications
 

DO_Pls-0382.jpg

Melita IRVING
Group leader
Human integrated tumor immunology discovery engine (Hi-TIDe)

Department of oncology UNIL CHUV
Ludwig Institute for Cancer Research Lausanne

Phone +41 21 692 59 61
Fax +41 21 692 59 95
Email Melita.irving@unil.ch

Ludwig.jpg (Print)

 

 

Research interest

Our research focuses on the development of gene-engineered T cells, tailored to treat specific tumors, that enable or promote:

  1. tumor-targeting
  2. productive T-cell signaling and metabolic activity under suppressive conditions
  3. tumor microenvironment (TME) re-programming to foster immunity
  4. safety

Research group projects

We have developed a variety of novel chimeric antigen receptors (CARs ; hybrid receptors that activate T cells upon tumor antigen binding), as well as T-cell receptors (TCRs), for T-cell engineering purposes, having strong clinical potential in terms of specificity, functionality and safety. We have also identified several promising molecules, both natural and rationally modified (and either expressed intracellularly or secreted) for improved in vivo tumor control and survival following the adoptive transfer of co-engineered TCR/CAR T cells (Figure 1). These molecules either directly promote T-cell activity and/or other protective immune infiltrate, and/or block/counteract various inhibitory mechanisms (low pH, cAMP, check-point ligands, etc.) in specific TMEs.

Moreover, important advances have been made by our group in vector design and T-cell transduction methodologies for improved gene-expression.

We have also developed a robust pre-clinical protocol for low-dose irradiation, rationally and optimally combined with immunotherapeutic drugs and antibodies based on TME characterization (gene-upregulation identified by Nanostring, qPCR, flow cytometry, immunohistochemistry etc.), for the treatment of advanced ovarian cancer which has been used as the rationale for a proposed clinical trial at the CHUV. Thanks to the Human-Tumor Immunology Discovery Engine (H-TIDE) platform, and close synergy between the CHUV-UNIL-SIB-EPFL, we have an unprecented opportunity to link patient bedside to benchwork & computer modeling in order to develop cutting-edge and powerful combinatorial immunotherapies to help cure patients. 

Irving1.jpg

Selected Publications

  • Irving M, et.al.,. 2017. Engineering CAR T-Cells for Racing in Solid Tumors; Don't Forget the Fuel. Front Immunol 8;267

  • Lanitis, E, et. al., 2017. Mechanisms regulating T-cell infiltration and activity in solid tumors. Ann Oncol.; in press

  • Santoro SP, et.al., 2014. T Cells Bearing a Chimeric Antigen Receptor against Prostate-Specific Membrane Antigen Mediate Vascular Disruption and Result in Tumor Regression. Cancer Immunol 3(1); 68-84

  • Irving M, et. al., 2012. Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness. J Biol Chem 287(27);23068-78

  • Irving M, et. al., 2010. Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J Immunol 184; 4936-4946

Group members

  • Dimitrios ALATZAGLOU
    PhD student
  • Kelly ASCENCAO
    Technician
  • Alexandre CASEL
    Technician
  • Elisabetta CRIBIOLI
    PhD student
  • Nahzli DILEK
    Postdoctoral scientist
  • Greta GIORDANO ATTIANESE
    Research associate
  • Isabel GRUBER
    BNF trainee
  • Gopinadh JAKKA
    Postdoctoral scientist
  • Fernanda HERRERA
    MD PhD student
  • Bahareh KHORAMDIN
    BNF trainee & technician
  • Konstantinos KIRITSIS
    Medical Master’s student
  • Evripidis LANITIS
    Postdoctoral scientist
  • Yang LIU
    Postdoctoral scientist
  • Magela MONTALVO BEREAU
    Visiting PhD Swiss Government fellow, CIM Cuba
  • Sandro MANNI
    Postdoctoral scientist
  • Bastien MARTI
    Civil service
  • Jesus Corria OSORIO
    MD PhD student
  • Patrick REICHENBACH
    Research technician
  • Kirsten SCHOLTEN
    Postdoctoral scientist
  • Bili SEIJO
    Research technician
  • Evangelos STEFANIDIS
    PhD student
  • Petros TYRAKIS
    Visiting MB/PhD medical student, University of Cambridge
  • Romain VUILLEFROY DE SILLY
    Postdoctoral scientist
  • Gwendoline WICKI
    Master’s student internship EPFL
Ch. des Boveresses 155 - CH-1066 Epalinges
Switzerland
Tel. +41 21 692 59 92
Fax +41 21 692 59 95
ludwig_cancer_research-logo.svg universite_de_lausanne-logo.svg chuv-logo.svg